74 related articles for article (PubMed ID: 33081907)
1. [Possibility of mesenchymal stem cell transplantation in the treatment of coronavirus disease 2019].
Yao M; Chen Z; He X; Long J; Guo W; Xing W; Xu X
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Sep; 32(9):1139-1144. PubMed ID: 33081907
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.
Akbari A; Rezaie J
Stem Cell Res Ther; 2020 Aug; 11(1):356. PubMed ID: 32795359
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
Yadav P; Vats R; Bano A; Bhardwaj R
Life Sci; 2020 Dec; 263():118588. PubMed ID: 33049279
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.
Yasamineh S; Kalajahi HG; Yasamineh P; Gholizadeh O; Youshanlouei HR; Matloub SK; Mozafari M; Jokar E; Yazdani Y; Dadashpour M
Stem Cell Res Ther; 2022 Jun; 13(1):257. PubMed ID: 35715852
[TBL] [Abstract][Full Text] [Related]
6. Stem cell therapy in coronavirus disease 2019: current evidence and future potential.
Shetty R; Murugeswari P; Chakrabarty K; Jayadev C; Matalia H; Ghosh A; Das D
Cytotherapy; 2021 Jun; 23(6):471-482. PubMed ID: 33257213
[TBL] [Abstract][Full Text] [Related]
7. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis.
Li Z; Niu S; Guo B; Gao T; Wang L; Wang Y; Wang L; Tan Y; Wu J; Hao J
Cell Prolif; 2020 Dec; 53(12):e12939. PubMed ID: 33098357
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis.
Kassem DH; Kamal MM
Front Cell Dev Biol; 2020; 8():587866. PubMed ID: 33102489
[TBL] [Abstract][Full Text] [Related]
9. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Zhou Z; Price CC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1407-1412. PubMed ID: 33094669
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience.
Caraffa R; Bagozzi L; Fiocco A; Bifulco O; Nadali M; Ponzoni M; Carrozzini M; Toscano G; Fraiese AP; Metra M; Lombardi CM; Serafini F; Ribola A; Jorgji V; Bottio T; Gerosa G
Eur J Cardiothorac Surg; 2020 Nov; 58(5):899-906. PubMed ID: 33084868
[TBL] [Abstract][Full Text] [Related]
11. Severe COVID-19 in Third Trimester Pregnancy: Multidisciplinary Approach.
Pelayo J; Pugliese G; Salacup G; Quintero E; Khalifeh A; Jaspan D; Sharma B
Case Rep Crit Care; 2020; 2020():8889487. PubMed ID: 33083063
[TBL] [Abstract][Full Text] [Related]
12. Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2).
Maveddat A; Mallah H; Rao S; Ali K; Sherali S; Nugent K
Int J Occup Environ Med; 2020 Oct; 11(4):157-178. PubMed ID: 33098401
[TBL] [Abstract][Full Text] [Related]
13. Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19.
Fantini J; Chahinian H; Yahi N
Biochem Biophys Res Commun; 2021 Jan; 538():132-136. PubMed ID: 33097184
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Mar; 40(5):2053-2066. PubMed ID: 33094701
[TBL] [Abstract][Full Text] [Related]
15. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
16. COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature.
Mahajan P; Dass B; Radhakrishnan N; McCullough PA
Cardiorenal Med; 2020; 10(6):462-469. PubMed ID: 33091905
[TBL] [Abstract][Full Text] [Related]
17. Immune Responses During Human Coronavirus Infection: Suggestions for Future Studies.
Arinola OG
Niger J Physiol Sci; 2020 Jun; 35(1):20-25. PubMed ID: 33084624
[TBL] [Abstract][Full Text] [Related]
18. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19.
Olaimat AN; Aolymat I; Al-Holy M; Ayyash M; Abu Ghoush M; Al-Nabulsi AA; Osaili T; Apostolopoulos V; Liu SQ; Shah NP
NPJ Sci Food; 2020; 4():17. PubMed ID: 33083549
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis.
Yousefifard M; Mohamed Ali K; Aghaei A; Zali A; Madani Neishaboori A; Zarghi A; Safari S; Hashemi B; Forouzanfar MM; Hosseini M
Iran J Public Health; 2020 Aug; 49(8):1411-1421. PubMed ID: 33083317
[TBL] [Abstract][Full Text] [Related]
20. Incomplete Trifascicular Block and Mobitz Type II Atrioventricular Block in COVID-19.
Gubitosa JC; Xu P; Ahmed A; Pergament K
Cureus; 2020 Sep; 12(9):e10461. PubMed ID: 33083164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
